Evidence map›Paper›PMID 27030262›Full record

ArticleJournal of virology2016

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.

Lalita Priyamvada, Alice Cho, Nattawat Onlamoon, Nai-Ying Zheng, Min Huang, Yevgeniy Kovalenkov, Kulkanya Chokephaibulkit, Nasikarn Angkasekwinai, Kovit Pattanapanyasat, Rafi Ahmed and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 123 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. CD4Vaccines · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Lalita PriyamvadaDepartment of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Alice ChoDepartment of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Nattawat OnlamoonDepartment of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nai-Ying ZhengDepartment of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Min HuangDepartment of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Yevgeniy KovalenkovDepartment of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Kulkanya ChokephaibulkitDepartment of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nasikarn AngkasekwinaiDepartment of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Kovit PattanapanyasatDepartment of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Patrick C WilsonDepartment of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Jens WrammertDepartment of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA jwramme@emory.edu.
Emory University · USMahidol University · THUniversity of Chicago · USSiriraj Hospital · TH

Funding

VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AHMED, RAFI · 2012 to 2022
$17.6M
Dengue Virus Infection in IndiaU01AI115651 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2015 to 2019
$4.0M
NIAID NIH HHS P01 AI097092NIAID NIH HHS U01 AI115651NIAID NIH HHS U19 AI057266
6 · The paper itself

Abstract

unlabelledDengue virus (DENV) infection results in the production of both type-specific and cross-neutralizing antibodies. While immunity to the infecting serotype is long-lived, heterotypic immunity wanes a few months after infection. Epidemiological studies link secondary heterotypic infections with more severe symptoms, and cross-reactive, poorly neutralizing antibodies have been implicated in this increased disease severity. To understand the cellular and functional properties of the acute dengue virus B cell response and its role in protection and immunopathology, we characterized the plasmablast response in four secondary DENV type 2 (DENV2) patients. Dengue plasmablasts had high degrees of somatic hypermutation, with a clear preference for replacement mutations. Clonal expansions were also present in each donor, strongly supporting a memory origin for these acutely induced cells. We generated 53 monoclonal antibodies (MAbs) from sorted patient plasmablasts and found that DENV-reactive MAbs were largely envelope specific and cross neutralizing. Many more MAbs neutralized DENV than reacted to envelope protein, emphasizing the significance of virion-dependent B cell epitopes and the limitations of envelope protein-based antibody screening. A majority of DENV-reactive MAbs, irrespective of neutralization potency, enhanced infection by antibody-dependent enhancement (ADE). Interestingly, even though DENV2 was the infecting serotype in all four patients, several MAbs from two patients neutralized DENV1 more potently than DENV2. Further, half of all type-specific neutralizing MAbs were also DENV1 biased in binding. Taken together, these findings are reminiscent of original antigenic sin (OAS), given that the patients had prior dengue virus exposures. These data describe the ongoing B cell response in secondary patients and may further our understanding of the impact of antibodies in dengue virus pathogenesis. IMPORTANCE: In addition to their role in protection, antibody responses have been hypothesized to contribute to the pathology of dengue. Recent studies characterizing memory B cell (MBC)-derived MAbs have provided valuable insight into the targets and functions of B cell responses generated after DENV exposure. However, in the case of secondary infections, such MBC-based approaches fail to distinguish acutely induced cells from the preexisting MBC pool. Our characterization of plasmablasts and plasmablast-derived MAbs provides a focused analysis of B cell responses activated during ongoing infection. Additionally, our studies provide evidence of OAS in the acute-phase dengue virus immune response, providing a basis for future work examining the impact of OAS phenotype antibodies on protective immunity and disease severity in secondary infections.

Indexed as

Cross ReactionsImmunologic MemoryAdolescentAdultAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody-Dependent EnhancementB-LymphocytesDengueDengue VirusEpitopes, B-LymphocyteFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopes, B-LymphocyteViral Envelope Proteins

Identifiers

PMID27030262
PMCPMC4886779
OpenAlexW2319464301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.